It has been reported that the PPAR-α agonist fenofibrate decreases AST gene expression and plasma levels in mice whereas the compound increases the expression and levels in human liver cells51, which may have counteracted a potential beneficial effect of elafibranor in NASH patients. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.